Thein uenzavaccine eldhasbeenconstantlyevolvingtoimprovethespeed,scalability,and exibilityofmanufacturing,andto
improvethebreadthandlongevityoftheprotectiveimmuneresponseacrossagegroups,givingrisetoanarrayofnextgeneration
vaccinesindevelopment.Amongthese,therecombinantinfluenzavaccinetetravalent(RIV4),usingabaculovirusexpressionvector
systemtoexpressrecombinanthaemagglutinin(rHA)ininsectcells,istheonlyonetohavereachedthemarketandhasbeen
studiedextensively.WedescribehowtheuniquestructuralfeaturesofrHAinRIV4improveprotectiveimmuneresponsescompared
toconventionalinfluenzavaccinesmadefrompropagatedinfluenzavirus.Inadditiontothesequenceintegrity,characteristicof
recombinantproteins,uniquepost-translationalprocessingoftherHAininsectcellsinstillsfavourabletertiaryandquaternary
structuralfeatures.Theabsenceofprotease-drivencleavageandadditionofsimpleN-linkedglycanshelptopreserveandexpose
certainconservedepitopesonHAmolecules,whicharelikelyresponsibleforthehighlevelsofbroadlycross-reactiveandprotective
antibodieswithrarespecificitiesobservedwithRIV4.Furthermore,thepresenceofuniformcompactHAoligomersandabsenceof
eggproteins,viralRNAorprocessimpurities,typicallyfoundinconventionalvaccines,areexpectedtoeliminatepotentialadverse
reactionstothesecomponentsinsusceptibleindividualswiththeuseofRIV4.Thesedistinctstructuralfeaturesandpurityofthe
recombinantHAvaccinethusprovideanumberofbenefitsinvaccineperformancewhichcanbeextendedtootherviraltargets,
suchasforCOVID-19.